Literature DB >> 24802173

Ketoconazole as an adrenal steroidogenesis inhibitor: effectiveness and risks in the treatment of Cushing's disease.

John Newell-Price1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24802173     DOI： 10.1210/jc.2014-1622

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  4 in total

1.  E2F1-mediated human POMC expression in ectopic Cushing's syndrome.

Authors:  Takako Araki; Ning-Ai Liu; Yukiko Tone; Daniel Cuevas-Ramos; Roy Heltsley; Masahide Tone; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2016-10-07       Impact factor: 5.678

Review 2.  Cushing's syndrome in childhood: update on genetics, treatment, and outcomes.

Authors:  Maya Lodish
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-02       Impact factor: 3.243

Review 3.  Cushing's syndrome: from physiological principles to diagnosis and clinical care.

Authors:  Hershel Raff; Ty Carroll
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

4.  EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.

Authors:  Takako Araki; Xiaohai Liu; Hiraku Kameda; Yukiko Tone; Hidenori Fukuoka; Masahide Tone; Shlomo Melmed
Journal:  J Endocr Soc       Date:  2017-01-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.